ArticleBlood advances2024

Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.

Inge van Outersterp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.